Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
3
75%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

completed250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

NCT04010968
terminatedphase_2

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT00801060
terminatedphase_2

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00391066
completedphase_1

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00868413

Clinical Trials (4)

Showing 4 of 4 trials
NCT04010968Phase 2

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

Completed
NCT00801060Phase 2

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Terminated
NCT00391066Phase 2

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

Terminated
NCT00868413Phase 1

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4